This case examines the leadership challenges faced by Nathalie Wappler, the new CEO of SRF, a public media company that operates in the German-speaking part of Switzerland and is part of the largest media company in Switzerland, SRG. The study spans the period from 2019 to 2021, capturing the seismic shift in corporate identity, disruptive changes in consumer behavior and the emergence of new players in the media industry. The central challenge revolves around two key questions: First, how to lead a traditional media organization towards the future while also maintaining its core amid industry disruption? And second, what leadership qualities are required to effectively navigate such a dual transformation? Drawing on a combination of internal strategy documents, along with publicly available information, the case highlights the strategic journey undertaken by Nathalie amidst the turbulence of the Covid-19 pandemic, and the broader challenge of leadership in the face of an unpredictable black swan-style event that becomes the new normal. It reveals that strategic decision making should not be paralyzed by incomplete data and emphasizes the importance of a robust and bold strategy combined with the right type of leadership. The findings underscore that Nathalie's leadership style, characterized by collaboration and inclusivity, was complemented by a clear vision and strong conviction. This framework enabled her to effectively navigate the transformational journey and overcome potential short-term derailments. Unique and unfiltered access to Nathalie and the SRF organization provide valuable insights, enabling students to explore the complexities of decision making in dynamic industries. The case prompts students to consider when to persevere, adapt or pivot, and encourages self-reflection on their own leadership adaptability in similar challenging scenarios.

Franck-Erik Flegbo and Cyril Le Terrien were already successful executives in a major multinational when they decided that it was time to dream, and to build their own company, with a culture that delivered performance, created a culture where everyone wanted to work, used the latest technologies, and did its part to save the planet. The opportunity to acquire 40-year-old Drinkotec came to them, and with it, they saw the vehicle for their dreams

The deal is closed; Franck-Erik Flegbo and Cyril Le Terrien become the owners of Drinkotec but discover that the existing team doesn't really have the capabilities or culture to innovate. The Covid-19 pandemic hits, and they discover that their customers need Drinkotec's help.

It is now four years later, and Drinkotec is scaling up fast. They've had to make some tough decisions in order to focus, have the best people and build the culture that they want, but today, major beverage companies are seeking their technology in order to go packaging-free. This case is about leadership, culture, sustainability and taking the leap to follow your dreams.

Dr Amin Shokrollahi, a mathematician who loves research, becomes an entrepreneur by accident. He discovers a software solution to decelerate Moore's Law, and his friend, entrepreneur Steve Papa, pushes him to create a company and bring the solution to market. For five years they "wander in the woods" building the team, raising money, developing the technology, fruitlessly talking with potential customers and working with some of the world's most important technology companies... but without commercial success.

Dr Amin Shokrollahi, a mathematician who loves research, becomes an entrepreneur by accident. He discovers a software solution to decelerate Moore's Law, and his friend, entrepreneur Steve Papa, pushes him to create a company and bring the solution to market. For five years they "wander in the woods" building the team, raising money, developing the technology, fruitlessly talking with potential customers and working with some of the world's most important technology companies... but without commercial success.

This case describes the journey of a new CEO bringing an innovative vision and strategy to a for-profit hospital under new ownership. It shows the application of a value-based health outcome approach in this setting, focused on the strategic approach, marketing and branding customer-centricity, and leadership challenges. The case describes key drivers: insurance reimbursement and cost pressures, shareholder ROI, consultant physician and surgeon demands, and patient needs and expectations.

Entrepreneur François Randin was successful, but searching for his next venture, wanting to build something sustainable. Suddenly he sees an all-electric sports car and decides to create an electric vehicle (EV) charging station company, even though the number of EVs on the road at the time is minuscule. He starts with software, moves to hardware, and launches... And then grows slowly until the day he discovers a new business model. He is successful in funding the start of the scaleup, but realizes that to really get to hyperscale (and fund his next idea), an adjacency, he needs really deep pockets. Raise more money, go for an IPO or accept one of the three acquisition offers he has in front of him?

Nathalie grappled with the divergent views in her head and from her team, evaluating a range of options: Persisting doggedly, halting completely, pausing temporarily, decelerating prudently or reconsidering and crafting a new strategy. The case discusses the cost of perseverance and provides an opportunity to explore the qualities of a CEO facing difficult choices in the face of public and private criticism during a global crisis.

Our story starts in 2001. Mike Caswell, an engineer and early Starbuck's employee, creates a technology that permits better flavor and increased margins, for fresh-roasted coffee in retail stores. Years of engineering and fundraising, franchising, disputes, hopes and frustrations ensue. Jamie Robertson joins in 2017, as both investor and CEO of a new unit in the UK and opens a store in London. The Covid pandemic hits, but Jamie perseveres, as he has realized that it is the customer experience that will make the difference. Jamie and his team open additional stores in London, Jamie is named CEO of the group, and eventually they are successful in raising significant funds for expansion in the UK and the US.

The case tells the story of Sami Arpa a young entrepreneur with a passion for the movie industry. Sami Arpa and his start-up Largo leverage technology to improve the movie industry. Largo launched in 2018 with the platform for short films called Sofy.tv. In 2020 Largo launches its own SaaS B2B platform providing an AI algorithm for the film-making industry. The algorithms support scriptwriters, producers, and artists with insights on the genre, content, and dramaturgy of their film, a character analysis, casting propositions, and a financial forecast. Largo's early success is confirmed by awards from the San Sebastian and Berlin Film Festival. It is central to evaluate geographical markets which could be attractive for Largo to play in such as Europe, the US, Latin America, India, and China. Facing in addition different new opportunities from a variety of industry segments such as advertising, broadcasting, scripts, and social media, the challenge is how to strategically focus given the resources at hand. Largo must position itself within the different geographical markets and the various industry segments to gain a competitive advantage against strong competitors like StoryFit and Cinelytic.

The case is based on published sources and was written in 2019, before the announcement in April 2021 of a breakaway European Super League. The idea of different formats and financing models for competition football is not new, however. The case explores this from the viewpoint of FC Bayern Munich the best-known and most successful German football club and one of the elite teams in Europe - and its president, Karl-Heinz Rummenigge, who has had a number of influential roles in the football world, in a career spanning more than five decades. Revenues from European football competitions have increased constantly over the last decades, with the UEFA European Champions League (UCL) constituting the largest piece of the cake. The big European football clubs, including Bayern Munich, aimed for a bigger share of the increasing revenues and debated a self-organized break-away European Super League (ESL) outside UEFA.

New management under CEO Bracken Darrell transformed Logitech into a company with a design-led focus. The product and brand portfolio are diversified with a strong focus on audio, video, gaming and other cloud-connected devices. This ultimately leads to a significantly lower dependency on the PC market, financial success, a transformed corporate culture, and high recognition in the industry. The strategy is not fundamentally different from the previous attempts, but the leadership style and strategy execution are radically changed. With the departure of key executives, Logitech and its CEO in 2019 are again at crossroads and are looking for new ways to grow.

Logitech has sold billions of computer mice and other computer peripherals over the 38 years of its existence. It was a typical growth company profiting on the success of the PC with an unprecedented history of top and bottom-line growth. With the decline in PC sales, Logitech needed a new strategy. Under the lead of new CEO Gerald Quindlen, the company developed a "Four- Screen" strategy and introduced two major post-PC products: a smart-TV-device named Logitech Revue (based on Google TV) and Lifesize, a high-end video collaboration solution. Both attempts failed dramatically and left the formerly highly successful company in a crisis.

Baabuk, a Swiss based start-up with a branded offering in wool footwear was founded in 2014 by the married couple Dan and Galina Witting. Since then and to 2018, the founders have grown the firm to now offer three product lines of wool footwear, employ 5 staff and book CHF 1.4 Mio net revenues from selling its products across online, distributor and retail channels. The case introduces Baabuk's history, current business and financial situation. The case also highlights the competitive environment with specific focus on Allbirds, a venture-capital backed US start-up. Allbirds has a similar core product to Baabuk. Whilst Baabuk has remained self-financed, Allbirds has raised a number of funding rounds with a most recent valuation of US1.4bn. The case presents the founders in a position where they feel the potential of the product has been clearly demonstrated but also face an increasingly competitive environment. Their primary concern is to formulate the right channel and pricing strategy, but they are also considering external investment to help scale the business. They are in a dilemma as to how to take Baabuk forward and wonder whether they are asking themselves the right questions.

An academic research group, providing services to medical device companies, had studied most of the new materials on the market and under development. They found a new approach for solving known issues related to the mending of damaged living tissue. The lab head and the research group leader knew this would be an opportunity to help a lot of patients and decided to patent the invention. Initial private investment in exchange for 50% IP rights allowed preclinical evaluation. Initial talks with large medical device companies indicated there was interest, but they needed clinical proof first. In collaboration with the University's TTO (technology transfer office), a start-up business plan was devised and venture capital (VC) funding was obtained, which allowed the new technology to get through the first clinical assessment. Dr. Gérard Bouchier, Research Group Leader, December 2008. Spirits were high that 15th of December morning. Gathering for coffee, the team went through their company presentation a last time. All hopes were set upon the meticulously planned VC syndicate meeting that could finally mean a step forward in starting up their medical device company. Having spent the last two years preparing the case, Gérard knew he was prepared. Unfortunately, despite the excellent reception of the case and the positive spirit around the table, none of the VC funds wanted to take the lead. Worse, about two weeks later the Great Financial Crisis hit the region and all funds pulled out of the discussion. What now? learning objective: 1/ How to set up and secure a motivated team of managers. 2/ How to organize the fund raising at an initial stage of development of a company, how to execute a strategic initiative, how to set the course and schedule the right resources, how to quickly adapt strategies in relation to changing environments. 3/ Applying leadership concepts and in particular organizational dynamics.

AM-Pharma is a biotech company developing a medicine for patients with acute kidney injury. The case describes the company's journey from inception in 2001 to a large deal with Pfizer in 2015. The aim is to discuss the value creation of AM-Pharma through its strategic decisions over time. It highlights the patient journey, company challenges, market size potential, and how the management team was able to raise multiple financing rounds from venture capitalists. It further provides the readers with a unique insight in the key risks and operational challenges of a biotech company and the value of an experienced management team backed by strong investors. The drug development process is inherently risky, long and expensive and the probability of commercializing a new drug is very low. The company's CEO is the protagonist and the case is split in three parts to provide the readers with surprises and open strategic questions which are time related. The case is semi-chronologically and a patient story is intermingled to provide a different perspective on clinical trials, ethical dilemmas and the high unmet medical need for new therapies. The case ends with a valuation simulation, in which the readers can negotiate the AM-Pharma/Pfizer deal themselves. Learning objective: The aim of the case study is to evaluate the value creation of AM-Pharma strategic decisions over time. 1/ The strategy diamond and Porter's Five Forces will be applied as a tool for understanding the industry and the company's strategy. 2/ The key success factors are also assessed for this challenging setting of a biotech startup. 3/ Role of Serendipity and management vision in opening new doors. 4/ Different exit options are discussed, highlighting pros, cons and what actually happened. 5/ How clinical outcome, and exit timing highly impact the valuation. The case will trigger discussions on the strategic options listed, and engage the students into exit negotiations simulation.

AM-Pharma is a biotech company developing a medicine for patients with acute kidney injury. The case describes the company's journey from inception in 2001 to a large deal with Pfizer in 2015. The aim is to discuss the value creation of AM-Pharma through its strategic decisions over time. It highlights the patient journey, company challenges, market size potential, and how the management team was able to raise multiple financing rounds from venture capitalists. It further provides the readers with a unique insight in the key risks and operational challenges of a biotech company and the value of an experienced management team backed by strong investors. The drug development process is inherently risky, long and expensive and the probability of commercializing a new drug is very low. The company's CEO is the protagonist and the case is split in three parts to provide the readers with surprises and open strategic questions which are time related. The case is semi-chronologically and a patient story is intermingled to provide a different perspective on clinical trials, ethical dilemmas and the high unmet medical need for new therapies. The case ends with a valuation simulation, in which the readers can negotiate the AM-Pharma/Pfizer deal themselves. Learning objective: The aim of the case study is to evaluate the value creation of AM-Pharma strategic decisions over time. 1/ The strategy diamond and Porter's Five Forces will be applied as a tool for understanding the industry and the company's strategy. 2/ The key success factors are also assessed for this challenging setting of a biotech startup. 3/ Role of Serendipity and management vision in opening new doors. 4/ Different exit options are discussed, highlighting pros, cons and what actually happened. 5/ How clinical outcome, and exit timing highly impact the valuation. The case will trigger discussions on the strategic options listed, and engage the students into exit negotiations simulation.

AM-Pharma is a biotech company developing a medicine for patients with acute kidney injury. The case describes the company's journey from inception in 2001 to a large deal with Pfizer in 2015. The aim is to discuss the value creation of AM-Pharma through its strategic decisions over time. It highlights the patient journey, company challenges, market size potential, and how the management team was able to raise multiple financing rounds from venture capitalists. It further provides the readers with a unique insight in the key risks and operational challenges of a biotech company and the value of an experienced management team backed by strong investors. The drug development process is inherently risky, long and expensive and the probability of commercializing a new drug is very low. The company's CEO is the protagonist and the case is split in three parts to provide the readers with surprises and open strategic questions which are time related. The case is semi-chronologically and a patient story is intermingled to provide a different perspective on clinical trials, ethical dilemmas and the high unmet medical need for new therapies. The case ends with a valuation simulation, in which the readers can negotiate the AM-Pharma/Pfizer deal themselves. Learning objective: The aim of the case study is to evaluate the value creation of AM-Pharma strategic decisions over time. 1/ The strategy diamond and Porter's Five Forces will be applied as a tool for understanding the industry and the company's strategy. 2/ The key success factors are also assessed for this challenging setting of a biotech startup. 3/ Role of Serendipity and management vision in opening new doors. 4/ Different exit options are discussed, highlighting pros, cons and what actually happened. 5/ How clinical outcome, and exit timing highly impact the valuation. The case will trigger discussions on the strategic options listed, and engage the students into exit negotiations simulation.

AM-Pharma is a biotech company developing a medicine for patients with acute kidney injury. The case describes the company's journey from inception in 2001 to a large deal with Pfizer in 2015. The aim is to discuss the value creation of AM-Pharma through its strategic decisions over time. It highlights the patient journey, company challenges, market size potential, and how the management team was able to raise multiple financing rounds from venture capitalists. It further provides the readers with a unique insight in the key risks and operational challenges of a biotech company and the value of an experienced management team backed by strong investors. The drug development process is inherently risky, long and expensive and the probability of commercializing a new drug is very low. The company's CEO is the protagonist and the case is split in three parts to provide the readers with surprises and open strategic questions which are time related. The case is semi-chronologically and a patient story is intermingled to provide a different perspective on clinical trials, ethical dilemmas and the high unmet medical need for new therapies. The case ends with a valuation simulation, in which the readers can negotiate the AM-Pharma/Pfizer deal themselves. Learning objective: The aim of the case study is to evaluate the value creation of AM-Pharma strategic decisions over time. 1/ The strategy diamond and Porter's Five Forces will be applied as a tool for understanding the industry and the company's strategy. 2/ The key success factors are also assessed for this challenging setting of a biotech startup. 3/ Role of Serendipity and management vision in opening new doors. 4/ Different exit options are discussed, highlighting pros, cons and what actually happened. 5/ How clinical outcome, and exit timing highly impact the valuation. The case will trigger discussions on the strategic options listed, and engage the students into exit negotiations simulation.